News Releases
In this section
-
May 2, 2002Insmed Incorporated Reports First Quarter Results
RICHMOND, Va., May 2, 2002 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq: INSM) today announced financial results for the quarter ended March 31, 2002. Revenues for the three months ended March...
-
Apr 26, 2002Insmed Incorporated to Webcast First Quarter Investor Update Conference Call; Friday, May 03, 2002, at 8:00 a.m. ET
ETRICHMOND, Va., Apr 26, 2002 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq:INSM), a biopharmaceutical company focused on the development of drug candidates for the treatment of type 2 diabetes...
-
Feb 18, 2002Insmed Incorporated and Oxagen Limited Form Partnership to Create a Genetic Study of Polycystic Ovary Syndrome
RICHMOND, Va. & ABINGDON, England, Feb 18, 2002 (BW HealthWire) -- Insmed Incorporated (NASDAQ: INSM) and Oxagen Limited, a privately held clinical genomics company, today announced a...
-
Feb 8, 2002Insmed Incorporated to Present at Wall Street Analyst Forum
RICHMOND, Va., Feb 8, 2002 (BW HealthWire) -- Insmed Incorporated (Nasdaq: INSM) today announced that Geoffrey Allan, Ph.D., President and Chief Executive Officer, will present an overview of the...
-
Jan 30, 2002Insmed Incorporated Reports Fourth Quarter and Year-end Financial Results
RICHMOND, Va., Jan 30, 2002 (BW HealthWire) -- Insmed Incorporated (Nasdaq: INSM) today announced financial results for the fourth quarter and year ended December 31, 2001. Fourth Quarter Results...
-
Jan 24, 2002Insmed Incorporated to Webcast Fourth Quarter Investor Update Conference Call; Thursday, January 31, 2002, at 8:00 a.m. ET -7 a.m. CT
RICHMOND, Va.--(BUSINESS WIRE)--Jan. 24, 2002--Insmed Incorporated (Nasdaq:INSM) will announce financial results for its 2001 fiscal year and fiscal fourth quarter approximately 4:00 p.m. EST on...
-
Jan 8, 2002Insmed Reports Positive Effects of SomatoKine in Subjects With Type 2 Diabetes
RICHMOND, Va., Jan 8, 2002 (BW HealthWire) -- Insmed Incorporated (Nasdaq: INSM) announced today positive results from a Phase II dose-ranging trial of SomatoKine® in patients with type 2...
-
Jan 3, 2002Insmed Appoints Vice President of Clinical Development
RICHMOND, Va., Jan 03, 2002 (BW HealthWire) -- Insmed Incorporated (NASDAQ: INSM) announced today the appointment of Fredrick L. Dunn, M.D., formerly of Novartis Pharmaceuticals Corp., as Vice...
Contact Us
